Outlook Therapeutics: Q3 Earnings Insights

Loading...
Loading...

Shares of Outlook Therapeutics OTLK moved higher by 2.8% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 133.33% year over year to ($0.07), which were in line with the estimate of ($0.07).

Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $320,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Recent Stock Performance

52-week high: $4.26

Company's 52-week low was at $0.58

Price action over last quarter: Up 15.56%

Company Profile

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...